ORAMED PHARMACEUTICALS INC. (ORMP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 1M 2M 3M Q4 '17: 2.5M Q1 '18: 2.5M Q2 '18: 2.5M Q3 '18: 2.4M Q4 '18: 2.5M Q1 '19: 2.6M Q2 '19: 2.6M Q3 '19: 2.7M Q4 '19: 2.7M Q1 '20: 2.7M Q2 '20: 2.7M Q3 '20: 2.7M Q4 '20: 2.7M Q1 '21: 2.7M Q4 '22: 2.7M Q1 '23: 2.7M Q2 '23: 2.7M Q3 '23: 2M Q4 '23: 1.3M Q4 '25: 2M Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21 Q2 '23 Q4 '25

Gross Profit TTM

0 5K 10K 15K Q4 '25: 13K Q4 '25

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q1 '20: -12.9M Q2 '20: -11.1M Q3 '20: -11.8M Q4 '20: -15.2M Q1 '21: -16M Q4 '22: -40.6M Q1 '23: -34.6M Q2 '23: -26.9M Q3 '23: -21.6M Q4 '23: -15.8M Q1 '24: -13.5M Q2 '24: -12.9M Q3 '24: -13.1M Q4 '24: -12.8M Q1 '25: -14.3M Q2 '25: -13.7M Q3 '25: -13M Q4 '25: -15.1M Q1 '26: -14.2M Q2 '26: -14.5M Q2 '20 Q1 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-60M 0 60M 120M 180M Q1 '19: -7.9M Q2 '19: 545K Q3 '19: -23M Q4 '19: -21.2M Q1 '20: -28.6M Q2 '20: -34.9M Q3 '20: -11.5M Q4 '20: -14.5M Q1 '21: -15.5M Q4 '22: -36.8M Q1 '23: -29.5M Q2 '23: -20.2M Q3 '23: -16.4M Q4 '24: -19.1M Q1 '25: -28.2M Q2 '25: -24.2M Q3 '25: 43.9M Q4 '25: 64M Q1 '26: 110M Q2 '26: 174.9M Q2 '19 Q1 '20 Q4 '20 Q1 '23 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 700K 1.4M 2.1M Q4 '16: 685K Q1 '17: 681K Q2 '17: 689K Q3 '17: 187K Q1 '19: 4K Q2 '19: 90K Q3 '19: 90K Q4 '25: 2M Q4 '16 Q1 '17 Q2 '17 Q3 '17 Q1 '19 Q2 '19 Q3 '19 Q4 '25

Operating Cash Flow TTM

-30M -20M -10M 0 10M 20M 30M Q4 '19: -11.8M Q1 '20: -13.6M Q2 '20: -13.2M Q3 '20: -12.4M Q4 '20: -15.6M Q4 '22: -27.9M Q1 '23: -24.3M Q2 '23: -18.5M Q3 '23: -16.9M Q4 '23: -10.3M Q1 '24: -6.2M Q2 '24: -1.5M Q3 '24: -7.9M Q4 '24: -8.4M Q1 '25: -10.5M Q2 '25: -16.1M Q3 '25: -10.6M Q4 '25: -9.1M Q1 '26: -8.5M Q2 '26: -5.2M Q1 '20 Q4 '20 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-30M -20M -10M 0 10M 20M 30M Q4 '19: -11.8M Q1 '20: -13.6M Q2 '20: -13.3M Q3 '20: -12.5M Q4 '20: -16M Q4 '22: -28.4M Q1 '23: -25M Q2 '23: -19.1M Q3 '23: -17.5M Q4 '23: -10.5M Q1 '24: -6.3M Q2 '24: -1.5M Q3 '24: -7.9M Q4 '24: -8.4M Q1 '25: -10.5M Q2 '25: -16.1M Q3 '25: -10.6M Q4 '25: -9.2M Q1 '26: -8.6M Q2 '26: -5.2M Q1 '20 Q4 '20 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 28M Q2 '21: 30.7M Q3 '21: 34.5M Q1 '22: 38.7M Q2 '22: 38.8M Q3 '22: 39.1M Q1 '23: 40M Q2 '23: 40.2M Q3 '23: 40.4M Q1 '24: 41.6M Q2 '24: 41.6M Q3 '24: 40.9M Q1 '25: 41.2M Q2 '25: 42.6M Q3 '25: 42.8M Q1 '26: 42M Q2 '26: 42.5M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -1.50 0.00 1.50 3.00 4.50 Q1 '19: 0.94 Q2 '19: 0.87 Q3 '19: 0.82 Q4 '19: 0.72 Q1 '20: 0.72 Q2 '20: 0.59 Q3 '20: 0.58 Q4 '20: 0.66 Q1 '21: 0.62 Q4 '22: -0.94 Q1 '23: -1.29 Q2 '23: -1.59 Q3 '23: -1.85 Q4 '24: -0.48 Q1 '25: -0.71 Q2 '25: -0.62 Q3 '25: 0.99 Q4 '25: 1.49 Q1 '26: 2.59 Q2 '26: 4.12 Q2 '19 Q1 '20 Q4 '20 Q1 '23 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.